August 2020 Clinical Watch Newsletter

September 2, 2020

Share this Flipbook
Facebook
Twitter
Email
LinkedIn

In this issue of Clinical Watch, we highlight Dravet syndrome and suggest prior authorization criteria for a new anticonvulsant medication. Lastly, we review claims data for off-label use of anticonvulsants by age in children.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

America’s Opioid Epidemic: Why Local Data Matters

Reassessing your CHNA and Implementation Strategies for COVID-19

Other content in this Stream

Assessing Your Core Administration Processing System

August 2020 Clinical Watch Newsletter

Previous Article

Next Article

Other content in this Stream

In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing

Advanced digital capabilities take the stress out of the busiest time of the year

In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding

In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi

Public health professionals have been sounding the alarm for years, but the COVID-19 pandemic and the sweeping protests following the death of George Floyd have brought the message front and center